Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Non-Current Assets (2019 - 2026)

C4 Therapeutics has reported Non-Current Assets over the past 8 years, most recently at $83.5 million for Q1 2026.

  • For Q1 2026, Non-Current Assets fell 4.02% year-over-year to $83.5 million; the TTM value through Mar 2026 reached $314.9 million, down 18.57%, while the annual FY2025 figure was $101.0 million, 9.94% up from the prior year.
  • Non-Current Assets for Q1 2026 was $83.5 million at C4 Therapeutics, down from $101.0 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $212.5 million in Q1 2022 and troughed at $58.6 million in Q3 2025.
  • A 5-year average of $112.9 million and a median of $105.0 million in 2024 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: soared 308.76% in 2022 and later tumbled 44.68% in 2023.
  • Year by year, Non-Current Assets stood at $143.3 million in 2022, then decreased by 26.54% to $105.3 million in 2023, then decreased by 12.76% to $91.8 million in 2024, then rose by 9.94% to $101.0 million in 2025, then dropped by 17.31% to $83.5 million in 2026.
  • Business Quant data shows Non-Current Assets for CCCC at $83.5 million in Q1 2026, $101.0 million in Q4 2025, and $58.6 million in Q3 2025.